Compare BRKR & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRKR | RDY |
|---|---|---|
| Founded | 1960 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 9.9B |
| IPO Year | 2000 | 2001 |
| Metric | BRKR | RDY |
|---|---|---|
| Price | $61.38 | $14.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 5 |
| Target Price | ★ $68.00 | $14.79 |
| AVG Volume (30 Days) | 2.5M | ★ 2.5M |
| Earning Date | 11-04-2026 | 10-23-2026 |
| Dividend Yield | 0.33% | ★ 0.44% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,895,600,000.00 | N/A |
| Revenue This Year | $3.00 | $4.58 |
| Revenue Next Year | $4.22 | $11.95 |
| P/E Ratio | ★ N/A | $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.37 | $11.36 |
| 52 Week High | $68.98 | $15.67 |
| Indicator | BRKR | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 52.10 | 69.38 |
| Support Level | $53.32 | $12.91 |
| Resistance Level | $63.77 | $15.08 |
| Average True Range (ATR) | 3.86 | 0.24 |
| MACD | 0.09 | -0.02 |
| Stochastic Oscillator | 45.55 | 73.30 |
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.